Sylvia Orandi
Family · Casselberry, FLNPI 1437503794
Payments from drug & device makers
Across 158 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$375
- AbbVie$251
- Astellas Pharma US Inc$217
- Abbott$192
- Exact Sciences$167
- Otsuka America Pharmaceutical, Inc.$147
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,076100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $375 |
| AbbVie | 13 | $251 |
| Astellas Pharma US Inc | 10 | $217 |
| Abbott | 9 | $192 |
| Exact Sciences | 4 | $167 |
| Otsuka America Pharmaceutical, Inc. | 8 | $147 |
| GSK | 9 | $138 |
| Eisai Inc. | 7 | $121 |
| Novo Nordisk | 6 | $114 |
| Pfizer | 6 | $111 |
| Novartis | 7 | $109 |
| Merck | 7 | $103 |
| Bayer | 5 | $91 |
| AstraZeneca | 6 | $87 |
| Amarin Pharma, Inc. | 4 | $79 |
| Daiichi Sankyo Inc. | 4 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Amgen | 3 | $48 |
| Lilly USA, LLC | 3 | $46 |
| Boehringer Ingelheim | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 3 | $41 |
| Sun Pharmaceutical Industries Inc. | 3 | $40 |
| Johnson & Johnson | 2 | $37 |
| Urovant Sciences Inc | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Boston Scientific | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Vivus LLC | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Silk Road Medical, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Solventum Corporation | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$122
- Cologuard Collection Kit$104
How this compares
$3,076 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 32 | $35,692 |
| TrulicityDulaglutide | 17 | $22,407 |
| EliquisApixaban | 18 | $20,063 |
| OzempicSemaglutide | 11 | $11,142 |
| VascepaIcosapent Ethyl | 13 | $6,699 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $1,384 |
| Gabapentin | 51 | $1,342 |
| SynthroidLevothyroxine Sodium | 24 | $1,093 |
| Levothyroxine Sodium | 96 | $887 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $861 |
| Losartan Potassium | 71 | $747 |
| Atorvastatin Calcium | 99 | $675 |
| Omeprazole | 31 | $659 |
| Alprazolam | 63 | $631 |
| Ventolin HfaAlbuterol Sulfate | 11 | $622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $43 | $35,69232 claims |
| Lilly USA, LLCTrulicity | $46 | $22,40717 claims |
| PfizerEliquis | $111 | $20,06318 claims |
| Novo NordiskOzempic | $114 | $11,14211 claims |
| AbbVieSynthroid | $251 | $1,09324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Casselberry
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.